RBFOX1 Regulates the Permeability of the Blood-Tumor Barrier via the LINC00673/MAFF Pathway

Shuyuan Shen,Chunqing Yang,Xiaobai Liu,Jian Zheng,Yunhui Liu,Libo Liu,Jun Ma,Teng Ma,Ping An,Yang Lin,Heng Cai,Di Wang,Zhen Li,Lini Zhao,Yixue Xue

DOI: https://doi.org/10.1016/j.omto.2020.03.014

2020-06-01

Abstract:<p>The blood-tumor barrier limits the delivery of therapeutic drugs to brain tumor tissues. Selectively opening the blood-tumor barrier is considered crucial for effective chemotherapy of glioma. RNA binding proteins have been emerged as crucial regulators in various biologic processes. This study found RBFOX1 was downregulated in glioma vascular endothelial cells derived from glioma tissues, and in glioma endothelial cells obtained by co-culturing endothelial cells with glioma cells. Overexpression of RBFOX1 impaired the integrity of blood-tumor barrier and increased the permeability of blood-tumor barrier. Meanwhile, RBFOX1 overexpression decreased the expression of tight junction proteins ZO-1, occludin, and claudin-5. The subsequent analysis of the mechanism indicated that the overexpression of RBFOX1 increased MAFF expression by downregulating LINC00673 which stabilized MAFF mRNA through the way of Staufen 1-mediated messenger RNA decay. Moreover, MAFF could bind to the promoter region and inhibit the promoter activities of ZO-1, occludin, and claudin-5, which reduced its' expression. The combination RBFOX1 upregulation and LINC00673 downregulation promoted doxorubicin delivery across blood-tumor barrier resulting in the apoptosis of glioma cells. In conclusion, this study indicated that overexpression of RBFOX1 increased blood-tumor barrier permeability through LINC00673/MAFF pathway, which might provide a new useful target for the future enhances blood-tumor barrier permeability.</p>